このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

UCB 将来の成長

Future 基準チェック /46

UCB利益と収益がそれぞれ年間27.7%と9.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に13.8% 28.1%なると予測されています。

主要情報

27.1%

収益成長率

27.8%

EPS成長率

Pharmaceuticals 収益成長	14.3%
収益成長率	9.9%
将来の株主資本利益率	14.0%
アナリストカバレッジ	Good
最終更新日	25 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BATS-CHIXE:UCBB - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	7,173	1,266	1,765	2,022	15
12/31/2025	6,431	864	1,387	1,646	17
12/31/2024	5,644	409	974	1,182	17
12/31/2023	5,182	343	445	761	N/A
6/30/2023	5,111	332	620	975	N/A
3/31/2023	5,279	376	684	1,047	N/A
12/31/2022	5,447	420	748	1,119	N/A
6/30/2022	5,854	887	982	1,462	N/A
3/31/2022	5,816	971	1,021	1,508	N/A
12/31/2021	5,777	1,055	1,060	1,553	N/A
9/30/2021	5,647	996	907	1,371	N/A
6/30/2021	5,517	936	754	1,188	N/A
3/31/2021	5,432	834	743	1,135	N/A
12/31/2020	5,347	732	732	1,081	N/A
6/30/2020	5,198	743	706	908	N/A
3/31/2020	5,056	767	647	895	N/A
12/31/2019	4,913	790	588	882	N/A
6/30/2019	4,686	652	677	950	N/A
3/31/2019	4,659	722	713	1,020	N/A
12/31/2018	4,632	792	748	1,089	N/A
6/30/2018	4,569	872	711	1,092	N/A
3/31/2018	4,522	812	715	1,010	N/A
12/31/2017	4,474	752	718	927	N/A
9/30/2017	4,400	708	N/A	N/A	N/A
6/30/2017	4,325	664	N/A	780	N/A
3/31/2017	4,236	604	N/A	604	N/A
12/31/2016	4,147	543	N/A	427	N/A
9/30/2016	4,051	439	N/A	N/A	N/A
6/30/2016	3,955	334	N/A	66	N/A
3/31/2016	3,916	299	N/A	156	N/A
12/31/2015	3,876	264	N/A	246	N/A
9/30/2015	3,773	266	N/A	388	N/A
6/30/2015	3,670	268	N/A	530	N/A
3/31/2015	3,507	192	N/A	541	N/A
12/31/2014	3,344	115	N/A	552	N/A
9/30/2014	3,206	114	N/A	507	N/A
6/30/2014	3,067	112	N/A	462	N/A
3/31/2014	3,100	97	N/A	375	N/A
12/31/2013	3,133	82	N/A	288	N/A
6/30/2013	3,413	153	N/A	128	N/A

アナリストによる今後の成長予測

収入対貯蓄率: UCBBの予測収益成長率 (年間27.7% ) は貯蓄率 ( 1.8% ) を上回っています。

収益対市場: UCBBの収益 ( 27.7% ) はUK市場 ( 13.2% ) よりも速いペースで成長すると予測されています。

高成長収益: UCBBの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: UCBBの収益 ( 9.2% ) UK市場 ( 3.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: UCBBの収益 ( 9.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: UCBBの自己資本利益率は、3年後には低くなると予測されています ( 13.8 %)。

UCB 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Recent updates

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

Dividend of €0.95 announced

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Revenue beats expectations

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €82.23

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB SA to Report Fiscal Year 2020 Results on Feb 25, 2021

UCB SA (ENXTBR:UCB) completed the acquisition of Ra Pharmaceuticals, Inc. (NasdaqGM:RARX) from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘